2026-10-07 · 2026-10 / week-1
Option Care’s $32.05 deal leaves no 10/5 long after the gap
Option Care’s $32.05 deal leaves no 10/5 long after the gap
Summary: CD&R and McKesson’s signed $32.05-per-share cash agreement puts a hard ceiling on OPCH’s current deal payoff. At the latest timestamped regular-session reference reviewed, $31.05 at 11:53 a.m. EDT on Oct. 6, the remaining gross upside is 3.2%; a return to the $23.37 Oct. 5 close if the deal breaks is a 24.7% downside stress. The announcement is meaningful, financing is committed, and closing is expected in H1 2027, but the terms do not clear the Desk’s long hurdle. Reject / U.S. long-only no-trade screen. Publication basis: Oct. 7, 2026, 00:43 SGT.
Opportunity Ranking
| Rank | Candidate | Direction | Mispricing | Evidence Freshness | Catalyst Window | Positioning | 10/5 Status | Tradeability | Main Rejection Risk |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Option Care Health (OPCH) | Long | $32.05 fixed cash consideration versus a $31.05 post-announcement reference; only 3.2% remains to the contractual amount | Oct. 6 definitive agreement and issuer disclosure; Oct. 6 11:53 a.m. EDT market mark | Shareholder and regulatory approvals; issuer expects H1 2027 close | Price spread mechanically implies about 88.5% completion under a two-state model; direct arb ownership, short interest and flows unknown | Reject: maximum current deal-close payoff +3.2%; failure stress -24.7%; 0.13:1 gross base/adverse | Nasdaq common stock; reported trading volume is not a current exit-capacity audit | Deal breaks, is delayed, or closes after a long wait; standalone value could be below the unaffected close |
| 2 | TeraWulf (WULF) | Long | Oct. 5 amendment doubles contracted Muskie power capacity to 1 GW and advances phase two by a year, but does not disclose a tenant lease, critical IT load, project economics or funded build | Oct. 5 issuer/SEC announcement; latest completed close $14.79 on Oct. 5 | Kentucky PSC approval, utility construction and later tenant/financing milestones; first phase still targets a 2028 ramp | No current positioning data; price/volume cannot identify who owns or hedges the story | Reject: the power announcement alone does not support a quantified +10% base or a ≤5% adverse bound | Nasdaq-listed, but project and funding gates dominate any near-term thesis | Capacity is not delivered IT capacity, contracted rent, revenue or cash flow |
| 3 | SPDR S&P 500 ETF (SPY) | Long | Broad-market control; no issuer-specific price/positioning/catalyst disagreement with a bounded 10/5 map identified | Oct. 5 regular close $774.97; Oct. 6 intraday reference available | No selected catalyst; index exposures remain subject to macro and concentration risk | Broad index positioning not assessed | Reject / not selected: no evidence-led asymmetric long setup | Highly traded fund, but liquidity does not create an edge | A broad rally can continue, but no differentiated catalyst or downside bound was established |
Selected opportunity: OPCH is the clearest measurable rejection, not the best executable long.
Why this one now: A fresh, signed cash deal makes the maximum success payoff observable. The price had already repriced sharply before this screen: the relevant comparison is the post-announcement $31.05 reference, not the prior $23.37 close used to advertise the 37% premium.
What should surprise the reader: The market mark is already close enough to the offer that the apparent 37% premium is no longer the investor’s prospective return. From $31.05, even certain payment of $32.05 is only +3.2%, before the time value of waiting until H1 2027.
Why This Is the Best Opportunity Right Now
The Oct. 6 announcement is a new primary-evidence boundary, not a refreshed quote on a prior Desk thesis. Option Care Health, CD&R and McKesson disclosed a definitive agreement: eligible common shares are to receive $32.05 in cash at closing. The issuer says closing is expected in the first half of 2027, subject to customary conditions including OPCH stockholder approval and required regulatory approvals. The joint release identifies five banks as providing committed financing to the consortium, which reduces—but does not eliminate—financing uncertainty.
OPCH is more decision-useful than WULF’s latest power-capacity amendment, where additional utility capacity precedes regulatory approval, construction, customer contracting, data-hall delivery and cash generation. SPY is the liquid control, not a fresh catalyst thesis. The merger spread is not automatically mispriced: under a simplified binary model, today’s discount can be read as a market-implied completion probability. The article’s finding is narrower: the remaining contractual upside cannot meet +10%, while the downside stress is much larger.
The strongest bull case is substantial. The target board unanimously approved the agreement; McKesson has a strategic rationale and a 49% investment; committed financing is disclosed; and the contractual cash amount is known. That supports a high chance of completion. But no financing commitment, board vote or regulatory process converts the $32.05 conditional payment into a current cash entitlement.
Why This Can Move More Than 5% Soon
The event already caused a large repricing: OPCH’s Oct. 5 regular close was $23.37, and the Oct. 6 11:53 a.m. EDT market reference was $31.05. The latter was up 32.9% from the prior close, with the deal price only $1.00 higher. A termination, failed vote, regulatory obstacle or material transaction change could remove much of the deal premium. The $23.37 close is a historical stress reference, not a floor or standalone valuation.
The immediate catalyst ladder is the definitive proxy and meeting schedule, required regulatory review, any agreement amendment, and closing. The issuer withdrew its previously disclosed 2026 guidance and said Q3 results are scheduled for Nov. 4, without a live call. That makes the next operating update less useful as a conventional guide-versus-consensus event; it does not change the fixed merger consideration.
The cheapest falsification test is to read the filed merger agreement and proxy when available, then verify the actual shareholder and regulatory path. A signed contract with committed financing is the strongest evidence against a break scenario; any newly disclosed condition, delay, litigation, remedy or recommendation change would require an immediate standalone downside refresh.
10/5 Asymmetry Gate
| Test | Result |
|---|---|
| Reference basis | $31.05 at 11:53:26 a.m. EDT, Oct. 6; timestamped intraday market reference, not an entry |
| Contractual top / highest-probability base | $32.05 cash if the merger closes; +3.2% gross before carry and costs |
| Failure stress | $23.37, Oct. 5 regular close before the deal announcement; -24.7%. Not fair value, a floor or a maximum loss |
| Simplified completion probability implied by reference | 88.5%, assuming only $32.05 on completion or $23.37 on failure; ignores carry, risk premium, other break values and path |
| Gross base/adverse ratio | 0.13:1 |
| Economics after costs | Not attractive: the maximum close payment is below the +10% base hurdle, and a long hold, spread, slippage and exit costs are not deducted |
| Execution | entry.price = null; execution.can_execute = false; current depth, venue quality and realistic exit capacity are not verified |
| Classification | Reject / no trade |
The 88.5% is arithmetic implied by the observed price under a two-outcome assumption, not a forecast or observed market consensus. With the selected reference values, a completion weight equal to that implied probability makes the weighted terminal price equal to the current mark by construction. It does not establish positive expected value after time and costs. Even a 100% close probability yields only 3.2% gross price upside.
What Should Surprise the Reader
The issuer-stated 37% premium compares $32.05 with the $23.37 Oct. 5 close before the transaction announcement. By the timestamped Oct. 6 market observation, the share price had already captured most of that jump. The published premium is a description of the announcement’s reference point, not a remaining return estimate.
A second distinction is that the deal announcement withdrew OPCH’s prior 2026 guidance. The $32.05 cash value does not depend on future reported earnings if the merger closes, but the standalone price after a failed transaction must be assessed against a business whose prior guidance has been withdrawn. That is one reason the $23.37 stress may understate or overstate the true break value; available evidence does not quantify it.
The Setup
Fact: The parties announced a definitive agreement on Oct. 6. The consideration is $32.05 cash per eligible common share, and completion would take OPCH private. OPCH’s board unanimously approved the deal. CD&R would own about 51%; McKesson would invest about $1.4 billion for about 49%. Five named banks are providing committed financing to the consortium.
Fact: The companies expect closing in H1 2027, subject to customary closing conditions including stockholder and regulatory approvals. The company says Q3 results are scheduled for Nov. 4 and that its previously disclosed 2026 guidance is withdrawn.
Inference: The $31.05 reference discount to $32.05 is consistent with a completion probability around 88.5% only under a deliberately simplified two-state model using $23.37 as the break reference. It is not a reliable probability estimate: the transaction has a long expected wait, the true break value is unknown, and market prices embed carry, risk aversion, flows and other paths.
Unknown: The full closing calendar, the outcome and duration of regulatory review, OPCH vote support, any remedy or litigation, the standalone value after termination, and current merger-arbitrage positioning. The definitive proxy and full transaction disclosures should resolve some—but not all—of these unknowns.
The Market Price
| Market item | Observation | Use and limit |
|---|---|---|
| OPCH regular-session reference | $31.05 at 11:53:26 a.m. EDT, Oct. 6 | ChartExchange time-stamped market-open snapshot; reference only, not a verified quote at publication |
| OPCH change from prior close | +$7.68 / +32.9% | Arithmetic from $23.37 Oct. 5 close; not an attribution of all trading to the release |
| OPCH intraday range / volume at snapshot | $30.97–$31.08 / 36.21M shares | Provider snapshot; not venue, volume-quality or exit-capacity evidence |
| Prior regular close | $23.37 on Oct. 5 | Before the Oct. 6 announcement; downside stress only |
| Cash consideration | $32.05 per eligible share | Conditional contractual payout, without additional upside modeled |
| Remaining gross deal spread | $1.00 / 3.22% from $31.05 | Before the wait to H1 2027, carry, fees, slippage and deal risk |
| SPY control | $774.97 regular close on Oct. 5 | ChartExchange broad-market control; not a like-for-like OPCH event-day move |
The SPY row is the Oct. 5 completed regular close and is used only as broad-market context. No live market-structure audit was used to infer an executable OPCH entry.
The Mispricing
The disagreement is between the deal’s conditional $32.05 payment and the post-announcement share price. The spread is not evidence that the market has missed an extra 10% of value: the contractual consideration caps the modeled close outcome, and the quote leaves only $1.00 per share before carry and costs.
Why might the market be wrong? It may be over-discounting a signed transaction backed by committed financing, unanimous target-board approval, and an acquirer with a stated strategic interest. Why might the market be right? Stockholder and regulatory approvals remain; the release itself lists delay, termination, litigation, business-disruption and other risks. The deal is expected to take months, pays no additional premium for waiting, and the underlying 2026 guidance has been withdrawn.
The price does not reveal an independent probability edge. The simple binary calculation yields 88.5% completion likelihood using the last unaffected close as the failure state, but changing the failure state or including carry changes that number. It is a translation of price into one model, not proof that the market is wrong.
The Positioning
The 32.9% move and unusually high reported volume are consistent with a merger-arbitrage repricing, but do not show who bought, who sold, which holders are hedged, or whether any forced flow remains. No current short-interest settlement, options open interest, fund flow, holder ownership, borrow, or dealer data were verified. Positioning is partially observed at best; investor identity and crowding remain unknown. A single intraday volume snapshot is not a positioning measure.
The Catalyst
| Step | State and timing | Observable test | Failure or delay path |
|---|---|---|---|
| Definitive merger agreement | Signed; announced Oct. 6, 2026 | Read the filed agreement, consideration, conditions, amendments and any termination notice | Amended terms, termination or breach changes the price map |
| OPCH stockholder approval | Pending; meeting date not verified | Definitive proxy, meeting date, vote recommendation and reported tally | Failed or delayed vote can terminate or extend the spread |
| Regulatory approvals | Pending; required approvals not itemized in the press-release summary | Track the agreement, agency notices and any remedy or litigation | Review, conditions or prohibition delay or prevent closing |
| Q3 2026 operating update | Scheduled Nov. 4; issuer withdrew prior 2026 guidance and says no live call | Read filed Q3 release; separate operating facts from transaction statements | Weak standalone results could lower break value; better results could support it |
| Closing/payment | Expected H1 2027, not completed | Confirm effective time, delisting and payment for eligible shares | Delay reduces annualized return; failure exposes standalone downside |
Cheapest falsification sequence: Review the filed merger agreement and proxy; confirm required approvals and vote date; update any regulatory or litigation development; compare the live quote with the fixed cash amount and a fresh standalone model. A press release repeating the strategic rationale is not a closing confirmation.
The Payoff
The only expression screened is unlevered OPCH common stock. If the deal closes and a share is eligible, the stated cash payment is $32.05. From the $31.05 reference, that is a 3.2% gross maximum price gain, before waiting through an expected H1 2027 closing window. The $23.37 pre-announcement close is used as a break stress only; the standalone share value could be materially lower or higher after termination.
Price Target and Probability Map
The map runs through June 30, 2027, the end of the issuer’s stated H1 expected-close period. Top and base both use $32.05 because the cash consideration is fixed; they differ only in timing. The bottom uses the Oct. 5 close as a historical failure stress, not fair value or a floor. The 10.0% / 78.5% / 11.5% weights are low-confidence scenario weights whose 88.5% aggregate completion probability is rounded from the market-implied two-state calculation. They are not independent or empirical probabilities.
| Scenario | Probability | Target / Level | Return / Payoff | Horizon | Conditions | Evidence Quality |
|---|---|---|---|---|---|---|
| Top Case | 10.0% | $32.05 | +3.2% | Through June 30, 2027 | Required approvals arrive early and the deal closes ahead of the issuer’s H1 window | Low; timing split is an assumption |
| Base Case | 78.5% | $32.05 | +3.2% | Through June 30, 2027 | Deal closes during the stated H1 2027 window | Medium for the contractual payout if closed; low for probability/timing |
| Bottom Case | 11.5% | $23.37 | -24.7% | Through June 30, 2027 | Deal fails and shares revisit the Oct. 5 pre-announcement close | Low; historical reference only, not a loss bound |
| Invalidation | n/a | Revised consideration, transaction termination, or final payment | Rebuild from the new agreement or standalone data | On new filing or closing | Verify the exact legal and settlement state | High once documented |
Probability-weighted expected value: $31.05 by construction under the rounded two-outcome market-implied close probability; 0.0% gross price return before carry and costs. With unrounded weights it equals the $31.05 reference exactly. This is not an independent forecast.
Current market level and timestamp: OPCH $31.05 at 11:53:26 a.m. EDT / 15:53:26 UTC, Oct. 6; regular-session market reference.
Primary instrument: OPCH common stock, screened only.
10/5 favorable base move: +3.2%, below +10%.
10/5 credible adverse move: -24.7% to the historical close stress; potential loss is not bounded at that level.
10/5 measurement basis: Reference-only; entry.price is null.
10/5 status: Reject / no trade.
Confidence: High that the current reference cannot meet the +10% base hurdle under the current cash terms; low on completion odds, timing and standalone break value.
Sensitivity and break-even
At a $23.37 failure value, the simplified probability required for zero gross price expectation is 88.5%: (31.05 − 23.37) ÷ (32.05 − 23.37). At 85% completion, the weighted price is $30.748, about -1.0% before carry and costs; at 95%, it is $31.616, about +1.8%. Even a 100% completion probability reaches only $32.05, or +3.2%. The deal therefore cannot clear the +10% base threshold from this reference without a new, higher contractual payment or a different verified entry basis; a higher bid is not assumed.
The Kill Shot
Strongest counterargument: This is not a vague expression of interest. A definitive agreement is signed; OPCH’s board unanimously approved it; McKesson will invest about $1.4 billion for roughly 49%; the consortium has committed financing from five named banks; and the target is expected to close within H1 2027. The announcement also describes a strategic healthcare-services rationale. Those facts may make a deal break less likely than the reference price’s simple 11.5% residual implies.
Why it still fails as a long: Completion odds cannot lift the cash payment above $32.05 under the current agreement. The maximum gain is +3.2% gross; the map’s break stress is -24.7%; gross base/adverse reward is about 0.13:1. Costs and an extended timetable only reduce the appeal. A high-quality company and a strong buyer do not change that asymmetry.
Load-bearing assumption: $23.37 is a useful break stress. It is simply the previous regular close, not intrinsic value. If standalone conditions have changed or merger-related restrictions damage the business, post-break price could be lower; if fundamentals are strong, it could be higher. This uncertainty widens risk rather than satisfying the 5% bound.
What Could Go Wrong
- Regulatory approvals, the shareholder vote, litigation, an amendment, a termination event or delay can erode or eliminate the cash spread.
- The $23.37 reference is not a floor; a failed deal could reprice OPCH below it.
- The expected wait runs into H1 2027 and the consideration has no modeled time-value payment. Financing, spread, fees and exit costs are unquantified.
- The company withdrew its 2026 guidance, weakening the standalone earnings anchor for a break scenario.
- Current positioning, borrow, spread, depth, venue quality and exit capacity were not verified; the high volume snapshot is not proof of reliable liquidity at size.
What Would Prove This Wrong
The no-trade conclusion would need a new evidence boundary: a higher signed per-share consideration, a verified lower current entry that still leaves +10% base upside without a >5% adverse path, or a fundamentally supported standalone floor that materially reduces break risk. A successful proxy vote or one regulatory clearance would improve completion evidence but, by itself, would not make the fixed $32.05 payment exceed the +10% hurdle.
Risk Audit
This is a reference-only merger-spread calculation, not an executable arbitrage recommendation. The quote is an intraday provider snapshot, not a current consolidated NBBO at the time of publication. No depth, venue-quality, volume-quality or realistic exit-size study was performed. A halt, headline gap, failed vote or regulatory development could bypass any stop. The unaffected close is not protection, and no price-based order can make the deal risk bounded. No options, leverage, margin, market order, price floor or execution instruction is supported.
Best Trade Strategy
No trade. Keep entry.price = null and execution.can_execute = false. Reassess only after reviewing the filed agreement and proxy, observing the approval path, rebuilding a standalone failure value, and obtaining fresh regular-session quote, spread, depth, venue and exit evidence. The current fixed consideration does not support a +10% long base case. No options, leverage, margin, market orders or price-floor language.
Sources
| Source | Date / timestamp | Use |
|---|---|---|
| Option Care Health / CD&R / McKesson joint announcement | Oct. 6, 2026, 8:00 a.m. EDT | Definitive $32.05 offer, board approval, 37% premium reference, expected H1 2027 close, required approval categories, guidance withdrawal, Q3 date, and committed financing statement |
| OPCH Oct. 6 timestamped market mark and Oct. 5 close | Oct. 6, 2026, 11:53:26 a.m. EDT | $31.05 market-open snapshot, displayed spread, reported volume and prior regular close; not execution capacity |
| Option Care Health SEC filing index | Oct. 6, 2026 | Confirms Oct. 6 Form 8-K; the filing and agreement should be reviewed directly for full closing conditions and termination provisions |
| Kentucky Power / TeraWulf expanded agreement notice | Oct. 5, 2026 | WULF candidate comparator: additional contracted demand, PSC condition and customer-credit commitment |
| TeraWulf Oct. 5 8-K exhibit | Oct. 5, 2026 | Confirms 500 MW to 1 GW contracted power and second phase timing subject to Kentucky PSC approval and utility construction |
| TeraWulf Q2 2026 results | Aug. 5, 2026 | Project and financial context for WULF comparison; not a current standalone valuation |
| WULF Oct. 5 regular-session history | Oct. 5, 2026, 4:00 p.m. EDT | $14.79 close and 36.73M reported shares; no causal attribution or volume-quality inference |
| SPY Oct. 5 regular-session history | Oct. 5, 2026, 3:59:59 p.m. EDT | $774.97 broad-market control close |
Research Quality Scorecard
| Criterion | Score | Basis |
|---|---|---|
| Market disagreement | 4/5 | Signed fixed-price offer versus a residual spread that mechanically embeds completion risk; not evidence of a valuation error |
| Evidence base | 5/5 | Same-day issuer transaction disclosure, timestamped market reference and filed-company data; full proxy and closing process remain pending |
| Positioning and flows | 3/5 | Price discount and volume observed, but holders, arb positioning, short interest and flows are unknown; capped at 3 |
| Catalyst path | 5/5 | Signed agreement, named approval gates, Q3 date and expected closing window are observable |
| Payoff architecture | 4/5 | Fixed maximum payout and historical break stress are computable, but standalone value and timing costs are not |
| Invalidation discipline | 4/5 | New agreement, proxy, approvals, delay, termination and settlement are monitorable; current downside anchor is weak |
| Differentiated insight | 4/5 | Separates the issuer’s announcement premium from the small payoff remaining after the price gap |
| Client value | 5/5 | Shows why a signed deal and liquid tape can still fail a long-only hurdle, with a replicable break-even probability calculation |
| Total | 34/40 | Publishable no-trade screen; failed 10/5 economics control classification |
Bottom Line
OPCH’s deal is real, but its headline premium is largely behind the buyer of shares at the Oct. 6 reference. The contract promises $32.05 only if conditions are satisfied, while the reference price leaves 3.2% gross upside and a much larger historical break stress. Committed financing strengthens the bull case but cannot lift the fixed payout above the 10% hurdle. Reject; no trade.
AI Illustration Prompt: Create a restrained financial-editorial illustration for The Mispricing Desk: a two-column merger ledger showing OPCH $31.05 REFERENCE beside CONDITIONAL CASH $32.05, with a short amber bracket labeled +3.2% GROSS and a separate dotted gray historical marker OCT. 5 CLOSE $23.37 — NOT A FLOOR. Add a slim timeline from OCT. 6 SIGNED to H1 2027 EXPECTED CLOSE, with three unfilled gates labeled SHAREHOLDERS, REGULATORY, and CLOSING. Use warm paper, graphite, deep navy and restrained amber; no green buy arrow, no guaranteed payout imagery, no price-floor motif. Add a subtle readable “The Mispricing Desk” watermark.